Anthracycline-Induced Cardiomyopathy
Key result
Heart failure therapy in anthracycline-induced cardiomyopathy yields ~42% LVEF recovery, linked to fewer cardiac events.
- P<0.001
- n=201
Why the study?
The natural history of anthracycline-induced cardiomyopathy and its response to modern heart failure therapy remained poorly defined, leaving evidence-based management recommendations lacking.
Does early initiation of heart failure therapy (enalapril and carvedilol) improve LVEF recovery and reduce cardiac events in patients with anthracycline-induced cardiomyopathy?
Population
201 consecutive patients with LVEF <=45% due to anthracycline-induced cardiomyopathy
Comparison
Prompt enalapril and, when possible, carvedilol after detection of LVEF impairment
Design
Cohort study
Follow-up
Mean 36 +/- 27 months
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Cardinale et al at the European Institute of Oncology showed that it was essential to initiate therapy at the first sign of CTRCD, because later initiation, even 6 months after the development of dysfunction, was less effective.”
Implication
May support immediate ACEI-beta-blocker therapy after LVEF drop; leaves open practice change pending randomized confirmation.
Key Points
- To assess the clinical course of anthracycline-induced cardiomyopathy and determine whether prompt initiation of modern heart failure therapy improves left ventricular ejection fraction and reduces adverse cardiac events.
- Enrolled 201 consecutive patients with anthracycline-induced cardiomyopathy defined by a left ventricular ejection fraction (LVEF) ≤45%.
- Initiated enalapril and, when feasible, carvedilol promptly following detection of LVEF impairment, monitoring LVEF over a mean follow-up of 36 ± 27 months.
- Classified patients as responders (complete recovery), partial responders, or nonresponders according to LVEF trajectory, and tracked cumulative major adverse cardiac events.
- Complete LVEF recovery occurred in 42% (n=85), partial recovery in 13% (n=26), and no recovery in 45% (n=90) of patients.
- The rate of responders declined as the delay between chemotherapy completion and treatment initiation increased, with no complete LVEF recovery observed after 6 months.
- Cumulative major adverse cardiac events were significantly lower in responders (5%) compared with partial responders (31%) and nonresponders (29%; p < 0.001).
Study Design
Type
Cohort (n=201)
Structured PICO
Does early initiation of heart failure therapy (enalapril and carvedilol) improve LVEF recovery and reduce cardiac events in patients with anthracycline-induced cardiomyopathy?
P
Population
201 consecutive patients with anthracycline-induced cardiomyopathy and LVEF ≤45% treated with heart failure therapy, followed for a mean of 36 months.
E
Exposure
Enalapril and, when possible, carvedilol promptly initiated after detection of LVEF impairment
O
Outcome
LVEF recovery (classified as complete, partial, or no recovery)surrogate
Main Result
p-value: p=<0.001
Prompt initiation of heart failure therapy (enalapril and carvedilol) early after the development of anthracycline-induced cardiomyopathy is associated with higher rates of LVEF recovery and fewer adverse cardiac events.
Cite This Study
Cardinale et al. (2010) conducted a cohort in Anthracycline-induced cardiomyopathy (n=201). Heart failure therapy (Enalapril and carvedilol) was evaluated on LVEF recovery and major adverse cardiac events (p=<0.001). Heart failure therapy in anthracycline-induced cardiomyopathy resulted in complete LVEF recovery in 42% of patients, who experienced fewer cardiac events than nonresponders (5% vs 29%; p<0.001).